

Stage 2:

Rational *in vivo* study selection may include:

- Mutagenic endpoints identified in Stage 1 *in vitro* tests
- Tumour target tissues in carcinogenicity studies
- Metabolic profile and SAR
- Potential for germ cell genotoxicity

Consider which Species, Tissues and Endpoints would give the most useful information

Devise and Justify Testing Strategy which may incorporate one of the following recommended assays:

1. Transgenic mutation test
2. Micronucleus assay
3. Comet assay

